Molecular Partners AG (NASDAQ: MOLN)
$6.53
+0.1800 ( +2.83% ) 0.8K
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Market Data
Open
$6.53
Previous close
$6.35
Volume
0.8K
Market cap
$219.02M
Day range
$6.46 - $6.73
52 week range
$3.32 - $12.70
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 4 | Jun 14, 2024 |
6-k | Quarterly Reports | 2 | Jun 11, 2024 |
6-k | Quarterly Reports | 2 | Jun 03, 2024 |
6-k/a | Quarterly Reports | 4 | May 17, 2024 |
6-k | Quarterly Reports | 4 | May 16, 2024 |
6-k | Quarterly Reports | 2 | Mar 26, 2024 |
20-f | Annual reports | 137 | Mar 14, 2024 |
6-k | Quarterly Reports | 2 | Jan 08, 2024 |
6-k | Quarterly Reports | 2 | Jan 05, 2024 |
6-k | Quarterly Reports | 2 | Dec 11, 2023 |